Tryngolza is once-monthly, subcutaneous RNA-targeted therapy and is expected to be available by the end of the year with a ...
A new study shows that nearly 90% of patients with moderate-to-severe atopic dermatitis (AD) reported their condition ...
The new, now-defeated bill eliminated the PBM reform measures included in a larger spending bill that the president-elect and ...
Anna Podolanczuk, M.D., M.S., discusses how the mortality rates for patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) are impacted by comorbidities, including ...
The Institute for Clinical and Economic Review assessed the formularies of 11 payers, covering 57 million people, to ...
Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...
The boxed warning follows a safety warning the FDA issued in September about the risk of liver injury from the use of Veozah ...
Women are more than twice as likely to develop post-traumatic stress disorder than men, and a new study demonstrates for the ...
Menopausal gay, lesbian and bisexual women are more likely to report recent sexual activity with less vaginal symptoms than ...
A new bill in Congress would require pass-through prices in both Medicare, and Medicaid and require transparency of PBM ...
A pooled analysis of two prior trials suggests patients with a variety of cardiac index scores saw improvement when Winrevair ...
If approved, clesrovimab would be the first and only FDA approved single dose immunization for infants approved in time for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback